Oral contraceptive therapy should be added to the list of those predisposing factors known to enhance yeast growth in the vagina.
Thirteen patients with yeast vulvovaginitis due to oral contraceptive therapy were seen during a six-month period. The potassium hydroxide (KOH) preparation confirmed the diagnosis in 11 of these patients; in selected patients, cultures were necessary. The germ-tube method of identification was rapid and efficient.
Accepted methods for treatment of yeast vulvovaginitis may be only temporarily effective unless the oral contraceptive is discontinued.
PORTER PS, LYLE JS. Yeast Vulvovaginitis Due to Oral Contraceptives. Arch Dermatol. 1966;93(4):402–403. doi:10.1001/archderm.1966.01600220014004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: